Activating HER3 mutations in breast cancerRosalin Mishra(University of Cincinnati Medical Center), Joan T. Garrett(University of Cincinnati Medical Center)OncotargetJune 11, 201810.18632/oncotarget.25576Cited by 36SaveCiteExport RISWatch citationsRelated PapersCurrent Advances in the Treatment of BRAF-Mutant Melanoma|Cancers|2020|172IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma|Cancers|2021|33HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers|PLoS ONE|2023|9RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells|Anti-Cancer Drugs|2023|6